Follow the PetIQ, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, PetIQ, Inc. has published 134 reports. The latest transaction was disclosed on 28 October 2024 (Disposition). Among the most active insiders: Smith Michael A. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 134 declarations
PetIQ, Inc. (ticker: PETQ) is a United States-based company that was listed on the NASDAQ market and operated at the intersection of animal health, consumer health products, and veterinary services. The company built its investment case around affordable access to pet care, and described itself in SEC filings as a leading pet medication, product, and wellness company. Its business model was organized into two reporting segments: Products and Services. The Products segment covered the manufacturing and distribution of pet medications and health-and-wellness products, while the Services segment provided veterinary wellness services and related product sales directly to consumers. PetIQ’s product platform was designed for scale. In its recent SEC filings, the company stated that its Products business distributed through more than 60,000 points of distribution across major U.S. retail and e-commerce channels. The portfolio included value-branded proprietary products as well as third-party brands for dogs and cats, spanning prescription medications, OTC medications, and wellness products. On the manufacturing side, PetIQ highlighted facilities in Omaha, Nebraska, and Springville, Utah, which supported domestic production and supply-chain control. The Services business gave the company a distinct omnichannel angle. PetIQ operated a national veterinarian service platform at over 2,600 community clinic locations and wellness centers hosted by retail partners across 39 states. Those locations offered diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks. In practice, this combination of products plus services allowed PetIQ to target recurring pet-owner spending and to differentiate itself from pure-play consumer health brands. Historically, PetIQ expanded through a mix of organic growth and strategic acquisitions, including the integration of veterinary-service capabilities that strengthened its retail and clinic footprint. Its competitive position was based on convenience, affordability, and broad retail penetration in the U.S. pet-health market. The company competed with large animal-health groups, private-label and branded consumer pet-product suppliers, and specialized veterinary service providers. Recent corporate developments were significant. In 2024, PetIQ reported improving profitability and then announced on August 7, 2024 that it had entered into a definitive agreement to be acquired by Bansk Group in an all-cash transaction valued at approximately $1.5 billion, or $31.00 per share. PetIQ later announced on October 25, 2024 that the acquisition had closed, and PETQ was delisted. For investors, that matters: the name now stands as a case study in scaled U.S. pet-health consolidation, rather than a continuing public-equity opportunity.